Sinopharm Accord sees H1 2025 revenue and profit drop

Sinopharm Accord reported a revenue of RMB 36,796,598,397.42 for the six months ended 30 June 2025, marking a 2.62% decrease from the same period last year. Net profit attributable to shareholders of the listed company fell by 10.43% to RMB 665,907,312.44. After deducting non-recurring gains and losses, net profit attributable to shareholders decreased by 9.63% to RMB 642,861,567.03.

Operating activities saw a drastic change, with net cash flow plummeting by 98.38% to RMB 15,066,690.28. Basic and diluted earnings per share each declined by 10.45% to RMB 1.20. The weighted average return on net assets also decreased by 0.49 percentage points, settling at 3.70%.

Despite the decline in profitability and cash flow, Sinopharm Accord's total assets grew by 6.04% to RMB 50,426,135,786.96 as of June 30, 2025. Net assets attributable to shareholders of the listed company also saw a 2.64% increase, reaching RMB 18,136,171,801.70.